



# **Comparison of Interlaboratory Computational Simulations of Flow and Blood Damage in the FDA Benchmark Blood Pump**

# **Introduction**

**Interlaboratory** were compared to bl inded CFD experiments predictions for both models. Previously, Stewart *et* assessed the FDA Nozzle Model submission. <sup>3</sup>

**The purpose of this study is to report the interlaboratory CFD study results for the** benchmark blood pump. TDA Benchmark Blood Pump

There are two FDA Benchmark Validation models:

- **1. Nozzle:**  simple geometric model w i t h a flow constriction
- **2. Blood Pump:** generic  centrifugal blood pump

### **Experimental Methods**

and turbulence intensities. The participants were blinded to the experimental turbulence model, and other computational parameters they deemed  $\frac{110W}{101}$  in the submission of 24 CFD results appropriate. This resulted in the submission of 24 CFD results.

# **Materials and Methods**

The blood pump was fixed in a loop, shown in **Figure 1A**, allowing for particle image velocimetry and hemolysis experiments to be separately performed at six pump operating conditions (**Fig. 1B**). The pump pressure head, velocity fields, and plasma free hemoglobin (fHb) were measured at each condition.

To rely on computational fluid dynamics (CFD) for regulatory submissions, their credibility must first be demonstrated through verification and validation (ASME V&V40, FDA Guidance). 1,2 40mm

**Figure 1.** FDA benchmark blood pump **A.** experimental flow loop (adapted from Hariharan *et al*.) 4 and **B.** six pump operating conditions.

### **Interlaboratory Computational Methods**







Sailahari V. Ponnaluri<sup>1</sup>, Prasanna Hariharan<sup>1</sup>, Luke H. Herbertson<sup>1</sup>, Richard A. Malinauskas<sup>1</sup>, Keefe B. Manning<sup>2,3</sup>, Brent A. Craven<sup>1</sup> **<sup>1</sup>**Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration **2Department of Biomedical Engineering, Pennsylvania State University 3Department of Surgery, Penn State Hershey Medical Center** 

# **Materials and Methods (cont.) The Context Con**

first anonymized to prevent **Scalar quantities** such as pressure head hemolysis were compared at all operating conditions using a [percent error.](https://apercenterror.To) To compare velocity fields, experimental and CFD data were interpolated common highresolution mesh and a global error (ε) (**EQ 1**)5 for Quadrant Quadrant 2, and the Diffuser was calculated (**Fig. 2**). Where 'u' was either the PIV or CFD velocity.

> Large variability in CFD predictions was observed predictions was obs<br>across all conditions.

submitted hemolysis results as t hey required custom codes.

predicted accurate fHb across all conditions (**Fig. 6A**)

### This study implies that CFD modeling of blood pumps should **be carefully validated across the entire range of relevant operating conditions for all quantities of interest.**



(EQ 1) 
$$
\varepsilon = \int_{0}^{1} \sum_{i=1}^{n} \left( \frac{u_{CFD,i} - u_{PIV,i}}{\max(u_{PIV})} \right)^{2}
$$

We thank Dr. Steven Day of the Rochester Institute of Technology who helped to design and fabricate the blood pump model in collaboration with RAM, and Dr. Sandy Stewart of the FDA for administering the interlaboratory CFD studies.

Test Condition



- -Turbulence model: k-ω SST (2), realizable k-ε (1), Spalart-Allmaras (2)
- -Steady (3) and transient models (2)
- -Moderately fine meshes: 11-16 million computational cells

 **Pump design and PIV data** *available at: [https://nciphub.org/wiki/FDA\\_CFD/ComputationalRoundRobin2Pump](https://nciphub.org/wiki/FDA_CFD/ComputationalRoundRobin2Pump)* 

common high-resolution mesh.



-greatest error for condition 4

No obvious dependence

- -mesh resolution
- -transient versus steady (**Fig. 3A**)

Three turbulence models generally performed well and were within two standard deviations for all six conditions (**Fig. 3B**)

- -k-ω SST
- -realizable k-ε
- -Spalart-Allmaras

**Figure 3:** Percent error associated with CFD pump pressure head  $|$  predictions when compared with experimental measurements as a function  $|$ of **A.** steady versus transient and **B.** turbulence models.

-seven used stressbased power law models and one used a strain-based model

Participants were more successful at predicting the relative index of hemolysis (RIH)

- -RIH was normalized by condition 5
- -Participants calculated RIH two ways (**Fig. 6B,C**)

**Figure 6: A.** CFD and  $|$ experimental absolute fHb **B.** RIH normalized by condition 5's fHb. **C**. RIH normalized by condition 5's modified index of hemolysis (MIH).







 $PIV$  Steady Transient  $-I<sup>0</sup>$ 

 $-5$ 

**Figure 5:** Planar velocity magnitude contours from PIV, a steady case, and  $|a\>$  transient case for Condition 5, demonstrating a velocity magnitude underprediction within the rotor for steady cases, as indicated by the arrows.

## **Discussion**

No single participant accurately predicted both pressure and velocity at all operating conditions.

Participants 2, 4, 14, 19, and 21 were within two standard deviations of pressure and 20% of velocity measurements at most operating conditions. In summary these participants used:

Participant 1 correctly predicted fHb at all operating conditions despite not accurately predicting pressure or velocity

# **Conclusion**

Some conditions or regions are more challenging to predict than others as demonstrated by condition 4 and the diffuser region of the FDA blood pump model. It is important that all intermediate quantities of interest, such as pressure and velocity, in addition to the final applicable biological parameters, be validated. As shown by participant 1, it is possible to accurately predict hemolysis despite having an incorrect velocity field and pump pressure head which are two parameters critical for decision making.

# **References**

1. ASME V&V 40-2018, *American Society of Mechanical Engineers*, 2018

2. CM&S Draft Guidance, FDA-2021-D-0980, 2022.

3. Stewart, S. F., et al, *Cardiovascular Engineering and Technology* 2012.

4. Hariharan, P., et al, *Cardiovascular Engineering and Technology* 2018.

## **Acknowledgements**

5. Ponnaluri, S. V. et al., *Annals of Biomedical Engineering,* 2022.

This project was funded by the FDA CDRH Critical Path program and, in part, by a National Science Foundation INTERN supplement through NSF CMMI-2017805.